[Form 4] Travere Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Christopher R. Cline, Chief Financial Officer of Travere Therapeutics, sold 470 shares of the company's common stock on 08/27/2025 at a price of $17.31 per share under a written plan intended to satisfy Rule 10b5-1(c). The filing reports 92,656 shares beneficially owned by Mr. Cline after the transaction.

The sale was executed pursuant to a 10b5-1 plan adopted on May 28, 2025 and included additional shares sold to cover the tax obligation arising from the vesting of performance-based restricted stock units that vested in May 2025. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 08/28/2025.

Positive

• Transaction executed under a 10b5-1(c) plan, indicating adherence to an established trading policy
• Sale was linked to tax withholding for vested PSUs, suggesting the disposition was compensation-related rather than opportunistic

Negative

• None indicated in the filing

Insights

Corporate Governance Expert

TL;DR: Routine insider sale under a pre-established 10b5-1 plan to cover tax from vested PSUs; governance procedures appear followed.

The Form 4 documents a small, planned disposition of 470 shares at $17.31 each under a 10b5-1(c) trading plan adopted May 28, 2025. The filing explicitly states the sale included additional shares to satisfy tax obligations from PSUs that vested in May 2025, indicating the transaction was not an opportunistic sale but a tax-cover event tied to compensation vesting. The use of a 10b5-1 plan and execution through an attorney-in-fact are consistent with standard governance controls for insider trading.

Securities Analyst

TL;DR: Transaction is informational and limited in size; it does not on its face indicate a material change in insider ownership.

The reported sale of 470 shares at $17.31 reduced the reporting person’s direct holdings to 92,656 shares. The document provides exact quantities and price but does not disclose any additional sales or changes to compensation arrangements beyond the PSU vesting note. Based solely on the disclosed figures, this appears to be a routine, non-material insider disposition executed under a pre-existing plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cline Christopher R.

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, STE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2025		S(1)		470	D	$17.31	92,656	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of additional shares to cover the tax obligation that occurred upon the vesting of performance-based restricted stock units (PSUs) that vested in May 2025.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Travere Therapeutics (TVTX) report for Christopher R. Cline?

The Form 4 reports that CFO Christopher R. Cline sold 470 shares of common stock on 08/27/2025 at $17.31 per share.

Why were shares sold by Christopher Cline according to the Form 4?

The filing states the sale was made under a 10b5-1(c) plan and included additional shares sold to cover the tax obligation from performance-based restricted stock units that vested in May 2025.

How many shares does Christopher Cline beneficially own after the reported transaction?

The Form 4 reports 92,656 shares beneficially owned by Christopher Cline following the transaction.

When was the 10b5-1 plan that governed the sale adopted?

The sale was made pursuant to a written plan adopted on May 28, 2025.

Who signed the Form 4 for the reporting person and when?

The Form 4 was signed by Elizabeth E. Reed, Attorney-in-Fact on 08/28/2025.